Press release

Galenica posts solid sales growth for 2013 and confirms double-digit growth in profit

Tuesday, 21 January 2014, ↓ directly to download

The Galenica Group increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013, in a market environment characterised by intense competition and sustained pressure on prices in various markets. All business sectors made good progress on important projects. Galenica
confirms its target of double-digit profit growth in 2013, taking into account one-time effects, for the 18th consecutive year, this both before and after deduction of minority interests.

_Among the highlights for the Pharma business sector were US Food and Drug Administration (FDA) approvals for Injectafer® (the US brand name of Ferinject®) for the treatment of iron deficiency anaemia, and for Velphoro® (PA21) to control serum phosphorus levels in patients with dialysis-dependent chronic kidney disease.

Ferinject® grew in all therapeutic areas, and total sales rose to CHF 158.2 million (+24.5%). The number of units sold (100mg) increased by 37% worldwide, with particularly solid growth achieved in major markets such as France (23%), Germany (16%), Great Britain and Ireland (44%), Spain (21%) as well as Switzerland (13%). Much remains to be done in terms of raising the awareness of iron deficiency among healthcare professionals. It takes time to develop and expand knowledge in this area, which is why providing information on the significance of iron deficiency in the various therapeutic areas remains a top priority.

_The Logistics, Retail and HealthCare Information business sectors also had a successful year. Highlights were the acquisition of Medifilm, a leading company in the field of blister packaging for medicines, as well as the acquisition of a minority stake in Bahnhof Apotheke Zurich, a pharmacy with an excellent position in the most heavily frequented place in Switzerland. Good progress was also made over the year on several projects introduced jointly by Logistics, Retail and HealthCare Information to increase effectiveness and efficiency.

2013 consolidated net sales of the Galenica Group (in million CHF)

2013

2012

in % 

Pharma

662.7

633.3

4.6

Logistics

2’118.2

2’102.3

0.8 

Retail

1’245.7

1’189.2

4.8

HealthCare Information

39.8

47.1

-15.5 

Net sales with other segments

(707.0)

(677.6)

 

Galenica Group

3’359.4

3’294.3

2.0

Continue

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).

Contact

Julien Vignot

Julien Vignot

Head Investor Relations


Galenica Ltd.

Investor Relations
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 81 11
Fax:
+41 58 852 81 12

Christina Hertig

Christina Hertig

Head of Corporate Communications


Galenica Ltd.

Corp. Communications
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 85 17
Fax:
+41 58 852 85 58

Send link

Send as link



Links

  •